Literature DB >> 27496977

Population Perspectives and World Health Organization Recommendations for CYD-TDV Dengue Vaccine.

Annelies Wilder-Smith1,2, Kirsten S Vannice3, Joachim Hombach3, Jeremy Farrar4,5, Terry Nolan4,6.   

Abstract

Keywords:  CYD-TDV vaccine; SAGE; World Health Organization; dengue; evidence-based guidelines; public health impact

Mesh：

Substances：

Year:  2016        PMID： 27496977     DOI： 10.1093/infdis/jiw341

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  20 in total

Review 1.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? There Is Only One True Winner.

Authors:  Scott B Halstead
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 2.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination.

Authors:  Stephen S Whitehead; Kanta Subbarao
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

3.  Potential Point-of-Care Testing for Dengue Virus in the Field.

Authors:  Wei-Kung Wang; Duane J Gubler
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

4.  Reply to Aguiar and Stollenwerk.

Authors:  Yang Yang; Ya Meng; M Elizabeth Halloran; Ira M Longini
Journal:  Clin Infect Dis       Date:  2018-02-01       Impact factor: 9.079

5.  Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.

Authors:  Wen-Yang Tsai; Hui-Ling Chen; Jih-Jin Tsai; Wanwisa Dejnirattisai; Amonrat Jumnainsong; Juthathip Mongkolsapaya; Gavin Screaton; James E Crowe; Wei-Kung Wang
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

6.  Innovative and New Approaches to Laboratory Diagnosis of Zika and Dengue: A Meeting Report.

Authors:  Adriana Goncalves; Rosanna W Peeling; May C Chu; Duane J Gubler; Aravinda M de Silva; Eva Harris; Maurine Murtagh; Arlene Chua; William Rodriguez; Cassandra Kelly; Annelies Wilder-Smith
Journal:  J Infect Dis       Date:  2018-03-13       Impact factor: 5.226

7.  Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines.

Authors:  Kirsten S Vannice; Annelies Wilder-Smith; Alan D T Barrett; Kalinka Carrijo; Marco Cavaleri; Aravinda de Silva; Anna P Durbin; Tim Endy; Eva Harris; Bruce L Innis; Leah C Katzelnick; Peter G Smith; Wellington Sun; Stephen J Thomas; Joachim Hombach
Journal:  Vaccine       Date:  2018-03-07       Impact factor: 3.641

8.  Dengue outbreaks in Hawai'i After WWII - A Review of Public Health Response and Scientific Literature.

Authors:  Rachel J Lew; Wen-Yang Tsai; Wei-Kung Wang
Journal:  Hawaii J Med Public Health       Date:  2018-12

9.  The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study.

Authors:  Stefan Flasche; Mark Jit; Isabel Rodríguez-Barraquer; Laurent Coudeville; Mario Recker; Katia Koelle; George Milne; Thomas J Hladish; T Alex Perkins; Derek A T Cummings; Ilaria Dorigatti; Daniel J Laydon; Guido España; Joel Kelso; Ira Longini; Jose Lourenco; Carl A B Pearson; Robert C Reiner; Luis Mier-Y-Terán-Romero; Kirsten Vannice; Neil Ferguson
Journal:  PLoS Med       Date:  2016-11-29       Impact factor: 11.069

10.  The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits.

Authors:  Jacqueline Deen
Journal:  PLoS Med       Date:  2016-11-29       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.